Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤CFO Richard Heppenstall receives options for 180,137 shares and 89,286 RSUs
- ➤Chief Product and AI Officer Anthony Jarc receives options for 132,464 shares
- ➤Anthony Jarc also receives 63,735 time-based RSUs
- ➤Options vest over four years; RSUs vest in three annual installments
CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that on September 28, 2026, it granted stock options to purchase 180,137 shares of the Company’s common stock and 89,286 time-based restricted stock units (“RSUs”) to Richard Heppenstall, the Company’s newly-hired Chief Financial Officer, as a material inducement to his employment.
The Company further announced that on October 1, 2026, it granted stock options to purchase 132,464 shares of the Company’s common stock and 63,735 time-based RSUs to Anthony Jarc, the Company’s newly-hired Chief Product and AI Officer, as a material inducement to his employment.
Get started
Create a free account to read the full story.